ライフサイエンスコーパス: postexposure

1 , with additional treatments on days 4 and 8 postexposure.

2 g the infection despite drugs at early times postexposure.

3 Dyspnea manifested 2 to 4 days postexposure.

4 , with additional treatments on days 4 and 8 postexposure.

5 d over 20 to 30 days and declined by 45 days postexposure.

6 IL-12 expression, which persisted up to 12 d postexposure.

7 dent increases in hair cell survival at 24 h postexposure.

8 hal respiratory tularemia when given 24-48 h postexposure.

9 precipitous decline in infection after day 7 postexposure.

10 tered in mice exposed to viable vs. HIC 48 h postexposure.

11 ilic airway inflammation that peaked at 18 h postexposure.

12 t lymphocyte decreases between days 8 and 11 postexposure.

13 CL10, CCL3, and CCL7 mRNA was sustained 18 h postexposure.

14 tic drops in their CD4(+) T cells by 2 weeks postexposure.

15 ually die via apoptosis starting 4 to 6 days postexposure.

16 rosolized Marburg virus was evident at 1 day postexposure.

17 f disease and quantitated for virus shedding postexposure.

18 prostates despite undetectable free BPA 1 hr postexposure.

19 xposure, immediately postexposure, and 20 hr postexposure.

20 posure and with distinct behavioral profiles postexposure.

21 both species succumbed between days 9 and 11 postexposure.

22 tection in multiple animal models up to 24 h postexposure.

23 ovascular function declined starting at 20 h postexposure.

24 outcomes during, immediately after, and 2 hr postexposures.

25 By 10 days postexposure, AChE-R prophylaxis markedly limited postex

26 mouse-adapted H3N2 strains, in both pre- and postexposure administration regimens.

27 pirometry was performed immediately pre- and postexposure and bronchoalveolar lavage (BAL) was obtain

28 vaccine is determined to be highly effective postexposure and if it is feasible, vaccinating househol

29 unoprotectant should be further pursued as a postexposure and potential therapeutic for Ebola virus e

30 Postexposure and preexposure geometric mean salivary cot

31 les immediately before and after the visits (postexposure) and on the following morning and analyzed

32 the brachial artery preexposure, immediately postexposure, and 20 hr postexposure.

33 ctant protein-3), and CCL11 (eotaxin) at 0 h postexposure, and expression of CXCL10, CCL3, and CCL7 m

34 These studies clearly demonstrate that postexposure antibody treatments can protect NHPs and op

35 At 3 days postexposure, AP-1 activation was elevated 10-fold in th

36 ated the generation of latent images without postexposure baking, providing a practical approach for

37 cyclobutane thymine dimer levels peaked 3 d postexposure, before returning to baseline.

38 Postexposure challenge of gammaHV68-infected I-A(b+/+) a

39 Postexposure challenge with recombinant vaccinia viruses

40 These postexposure changes endured into adulthood.

41 However, mean preexposure to postexposure changes were significantly (p < 0.02) large

42 Beginning around day 8 to day 10 postexposure, clinical signs consistent with encephaliti

43 ammatory responses in the mouse lung at 24 h postexposure compared to the fine and ultrafine PM, and

44 0 microM, 10 min) induced an inward current (postexposure current; Ipe) which was associated with a C

45 ladder, and joint tissue obtained at 8 weeks postexposure did not reveal greater pathology in mice in

46 Postexposure discrimination of other stimuli was unaffec

47 before virus exposure, followed by a booster postexposure dose.

48 ort, significant valvular disease on initial postexposure echocardiography was common in this cohort;

49 ly attractive candidates due to their proven postexposure efficacy in nonhuman primate models of EBOV

50 e, the bivalent vaccine has slightly reduced postexposure efficacy most likely due to its restricted

51 Initial in vivo evaluation of postexposure efficacy of our inhibitors combined with an

52 Significant postexposure efficacy of several MAbs, including a novel

53 rior to bacterial colonization (1 to 14 days postexposure), enriched fecal cultures were more sensiti

54 No postexposure etching or bonding is required; the channel

55 The postexposure fluorescence quenching as well as the sensi

56 oxidizing reagents did not demonstrate this postexposure fluorescence quenching; rather, a recovery

57 nical signs were fever developing 24 to 40 h postexposure followed by leukocytosis resulting from a h

58 amples were collected pre-exposure and daily postexposure, for up to 13 d.

59 scores compared with baseline and had higher postexposure global scores than the sunscreen group (0.7

60 ate that convalescent FFP shows promise as a postexposure HPS prophylactic.

61 The postexposure IgG treatment was completely protective, wi

62 Pre- and immediate postexposure images of the photoreceptors and RPE cells

63 nd also demonstrate the potential value of a postexposure immunoprophylactic to treat individuals aft

64 mework for humanization and development of a postexposure immunotherapeutic.

65 immunizations or provide protection through postexposure immunotherapeutics are long-sought goals.

66 virus infections, both prophylactically and postexposure in a homologous challenge setting.

67 e macrophage concentration were present 48 h postexposure in human subjects and at 96 h postexposure

68 h postexposure in human subjects and at 96 h postexposure in mice.

69 The results represent successful postexposure in vivo efficacy by a mAb mixture and sugge

70 xposure, AChE-R prophylaxis markedly limited postexposure increases in plasma murine AChE-R levels wh

71 Cellular responses were monitored with postexposure incubation in submerged conditions, reveali

72 of the blast OPW-produced energy waves with postexposure inflammatory events has not yet been deline

73 el, safe, and effective emergency therapy of postexposure inhalation anthrax.

74 CD4 and CD8 cell apoptosis as early as 12 h postexposure; inhibition of CD4 and CD8 cell cycle progr

75 mpared by vaccine exposure status during the postexposure interval.

76 a new model for evaluating prophylactic and postexposure interventions prior to testing in NHPs.

77 re isolates ranged from <0.5 to 1.85 and for postexposure isolates from <0.5 to 2 uM.

78 ade regarding smallpox vaccination, therapy, postexposure isolation and infection control, hospital e

79 to 3 days postexposure; midinfection, 5 days postexposure; late infection, 7 to 9 days postexposure)

80 ersus 22.7 ng/ml, p < 0.05), and at the 2-wk postexposure lavage (NL3) it had declined to 24.2 ng/ml

81 avage neutrophils was present in the initial postexposure lavage in both human subjects and mice.

82 The demonstration of successful postexposure MAb 201 therapy in an animal model that dem

83 lesticks including universal precautions and postexposure management of occupational HIV, hepatitis B

84 ns at high risk for infection or who require postexposure management.

85 spores, particularly if not done immediately postexposure, may not be very effective for detecting B.

86 Pre- and postexposure measurements were compared, and Pearson cor

87 tage induction (early infection, 1 to 3 days postexposure; midinfection, 5 days postexposure; late in

88 urvival, whereas it induced mild to moderate postexposure mortality in the larval stage and at metamo

89 haryngeal lymphoid tissues at 1 and 2 months postexposure (MPE).

90 strain CO92 and necropsied at 24-h intervals postexposure (p.e.).

91 al changes were identified as early as day 3 postexposure (p.e.).

92 an pediatric AIDS, the potential of pre- and postexposure passive immunization with hyperimmune serum

93 08, through December 31, 2010 (3 years); the postexposure period, January 1 through December 31, 2011

94 or ciprofloxacin may be useful in the early postexposure period.

95 cer and will be superior vaccine choices for postexposure poxvirus vaccination, as they also provide

96 photoresist SU-8, and following exposure and postexposure processing, the resulting SU-8 features had

97 immediately after exposure but reduced 24 h postexposure proliferation.

98 ing that these organisms have potential as a postexposure prophylactic.

99 here are no FDA-licensed vaccines, effective postexposure prophylactics, or therapeutics.

100 d or body fluid exposures that might warrant postexposure prophylaxis (e.g., needlestick injury to a

101 Nonoccupational postexposure prophylaxis (nPEP) is recommended after a s

102 Postexposure prophylaxis (PEP) after intravaginal exposu

103 The feasibility of providing postexposure prophylaxis (PEP) after sexual or injection

104 We determined the efficacy of postexposure prophylaxis (PEP) and treatment of ill inde

105 rates for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP) are low.

106 guidelines for human immunodeficiency virus postexposure prophylaxis (PEP) are the first to combine

107 rld Health Organization (WHO) guidelines for postexposure prophylaxis (PEP) developed recommendations

108 In the mouse models, the postexposure prophylaxis (PEP) efficacy obtained with th

109 Antibiotic postexposure prophylaxis (PEP) following pertussis expos

110 velopment Group meeting, recommendations for postexposure prophylaxis (PEP) for human immunodeficienc

111 e individuals who present for antiretroviral postexposure prophylaxis (PEP) had a 1-time exposure to

112 Preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) has been shown to be effe

113 ed regimens for human immunodeficiency virus postexposure prophylaxis (PEP) has evolved over the last

114 arter packs for human immunodeficiency virus postexposure prophylaxis (PEP) is practiced in many sett

115 Rabies virus (RABV) postexposure prophylaxis (PEP) requires rapid vaccine-in

116 us (RV) research is to develop a single-dose postexposure prophylaxis (PEP) that would simplify vacci

117 The efficacy of antiretrovirals as postexposure prophylaxis (PEP) to prevent viral acquisit

118 New recommendations for rabies postexposure prophylaxis (PEP) were published by the Cen

119 screening for urine/kidney exposure; and (5) postexposure prophylaxis (PEP) when indicated.

120 HIV or hepatitis B virus exposures includes postexposure prophylaxis (PEP) when necessary; however,

121 In a nonrandomized study of nonoccupational postexposure prophylaxis (PEP), a cross-sectional evalua

122 CDC) recommendations advocating occupational postexposure prophylaxis (PEP), health care workers are

123 of mother-to-child transmission (PMTCT), and postexposure prophylaxis (PEP)-are all strongly recommen

124 ys have not been evaluated in the setting of postexposure prophylaxis (PEP).

125 y and efficacy of antiretroviral options for postexposure prophylaxis (PEP).

126 or PrEP compares favorably with evidence for postexposure prophylaxis (PEP).

127 fied for its potential application in rabies postexposure prophylaxis (PEP).

128 detected in their serum after completion of postexposure prophylaxis (range, 0.3-40.8 IU/mL).

129 Rabies postexposure prophylaxis (RPEP) treatments and associate

130 Postexposure prophylaxis 4 days after challenge was 100%

131 cal personnel or family members who required postexposure prophylaxis after coming in contact with an

132 1R-specific neutralizing antibodies afforded postexposure prophylaxis after systemic vaccinia virus i

133 e results are encouraging for antibody-based postexposure prophylaxis and support the notion that ant

134 infrastructure prevents timely reporting and postexposure prophylaxis and the ubiquity of domestic an

135 In both postexposure prophylaxis and treatment of acute infectio

136 Both postexposure prophylaxis and treatment of varicella are

137 ies is a novel finding with implications for postexposure prophylaxis and vaccines.

138 igational agent rVSV-ZEBOV or TKM-100802 for postexposure prophylaxis and were monitored in the Unite

139 rhoeae or C. trachomatis, and the use of HIV postexposure prophylaxis are discussed.

140 None of the 32 patients with rabies received postexposure prophylaxis before the onset of clinical di

141 Postexposure prophylaxis can offer protection against HI

142 Our findings show that postexposure prophylaxis can successfully prevent hepati

143 ic data in humans, AVI-7288 has potential as postexposure prophylaxis for MARV infection in humans.

144 , there are no national guidelines regarding postexposure prophylaxis for nonoccupational exposures.

145 The use of postexposure prophylaxis for occupational and perinatal

146 clinical trials to prove the efficacy of ART postexposure prophylaxis has not been possible.

147 Clinicians should consider initiating postexposure prophylaxis in adolescents for any oral, an

148 eded to characterize the use and efficacy of postexposure prophylaxis in an adolescent population.

149 easonable alternative to immune globulin for postexposure prophylaxis in many situations.

150 Further evaluation of 694/98-D for postexposure prophylaxis in mice revealed that 694/ 98-D

151 us type 1 (HIV-1) was evaluated for pre- and postexposure prophylaxis in SCID mice reconstituted with

152 imely distribution of effective treatment or postexposure prophylaxis in the aftermath of the release

153 Postexposure prophylaxis is an effective intervention to

154 lock lentivirus infection, but their role in postexposure prophylaxis is poorly understood.

155 Postexposure prophylaxis is recommended for all persons

156 Postexposure prophylaxis is the primary means of treatin

157 inoculated, and it is decreased by 79% when postexposure prophylaxis is used.

158 ssion of HIV after sexual abuse is rare, HIV postexposure prophylaxis must be administered in a timel

159 ry HIV infection suggested that a vaccine or postexposure prophylaxis of at least 95% efficacy would

160 canine rabies but also for late-stage rabies postexposure prophylaxis of humans.

161 Postexposure prophylaxis of inhalational anthrax require

162 ccine candidate for both the preexposure and postexposure prophylaxis of rabies.

163 designed primarily to estimate the effect of postexposure prophylaxis on preventing influenza illness

164 The postexposure prophylaxis protocol used at the University

165 Although current postexposure prophylaxis rabies virus (RV) vaccines are

166 ansfer experiments in mice, both in pre- and postexposure prophylaxis regimens.

167 f VNAs to protect against RABV infections in postexposure prophylaxis settings, these findings may he

168 of mucous membranes with infectious saliva, postexposure prophylaxis should be considered if the his

169 Candidates for postexposure prophylaxis should be identified and given

170 When indicated, postexposure prophylaxis should be started as soon as po

171 Postexposure prophylaxis should follow region-appropriat

172 immunodeficiency virus type 1 (HIV) pre- and postexposure prophylaxis show promise.

173 Here, we evaluated the feasibility of two postexposure prophylaxis strategies in the ANDV/hamster

174 utralizing activity against HIV and provided postexposure prophylaxis to hu-peripheral blood leukocyt

175 immunodeficiency virus (HIV) nonoccupational postexposure prophylaxis using an algorithm to assess th

176 Postexposure prophylaxis using rabies immune globulin an

177 milial contacts of the patients who received postexposure prophylaxis was 54 per patient (range, 4 to

178 Rabies postexposure prophylaxis was considered inappropriately

179 V); 4 neonates were then given intramuscular postexposure prophylaxis with 3 anti-HIV human neutraliz

180 Despite postexposure prophylaxis with antibiotics, inhalation of

181 t product B, product recalls took place, and postexposure prophylaxis with both hepatitis A virus vac

182 Postexposure prophylaxis with zidovudine appears to be p

183 ne globulin is a crucial component of rabies postexposure prophylaxis, and here we also show that it

184 l contexts, including maternal transmission, postexposure prophylaxis, and sexual transmission (topic

185 Rabies can be prevented with prompt postexposure prophylaxis, but this is costly and often i

186 ction, indications for vaccination, therapy, postexposure prophylaxis, decontamination of the environ

187 for vaccination, therapy for those exposed, postexposure prophylaxis, decontamination of the environ

188 ctive antimicrobial agents for treatment and postexposure prophylaxis.

189 sure to communicable diseases for receipt of postexposure prophylaxis.

190 romised children to varicella often requires postexposure prophylaxis.

191 e has similar efficacy to immune globulin as postexposure prophylaxis.

192 es prevention after an animal bite is prompt postexposure prophylaxis.

193 the incidence of rabies is low, many receive postexposure prophylaxis.

194 rs for preventing HIV-1 transmission and for postexposure prophylaxis.

195 HIV exposure, similar to recommendations for postexposure prophylaxis.

196 present to health care workers too late for postexposure prophylaxis.

197 anagement of exposures including the role of postexposure prophylaxis.

198 rter incubation periods if they had received postexposure prophylaxis.

199 ents experienced self-limited symptoms after postexposure prophylaxis; none developed Ebola virus dis

200 ed needles, or recent use of nonoccupational postexposure prophylaxis; ongoing use of preexposure pro

201 This is the first demonstration of complete postexposure protection against an Ebola virus in nonhum

202 Postexposure protection against MARV in non-human primat

203 mselves for endosomal delivery and conferred postexposure protection against multiple ebolaviruses in

204 This complete postexposure protection against ZEBOV in non-human prima

205 us platform has been successful in providing postexposure protection in nonhuman primates.

206 Postexposure protection was only observed in vaccinated

207 Postexposure protocols can further protect potential res

208 promising strategy to develop a single-dose postexposure rabies vaccine where the generation of earl

209 Postexposure recovery of threshold sensitivity has been

210 out the course of infection from 1 to 9 days postexposure, representing the full course of the infect

211 uals, protection against smallpox during the postexposure revaccination period may require T cell mem

212 the potential of replacing current pre- and postexposure RV vaccines.

213 In the postexposure setting, intravenous administration of ETI-

214 is study we show, both in a preventative and postexposure setting, that humanized mice infected with

215 important for the protection against RABV in postexposure settings.

216 on against rabies virus (RABV) infections in postexposure settings.

217 We estimated the effectiveness of postexposure smallpox vaccination in preventing or modif

218 ics were critically reviewed and 3 different postexposure strategies were identified as being farthes

219 In therapeutic postexposure studies, human gamma globulin partially pro

220 These changes persisted for 24 h postexposure, suggesting heritable modifications.

221 Postexposure suppression of Ipe protected against NMDA t

222 ys postexposure; late infection, 7 to 9 days postexposure) that was led by a robust innate immune res

223 However, after colonization (40 or more days postexposure), the opposite was true and RAMS culture wa

224 At selected times postexposure, the amounts of GRO alpha produced by the c

225 fected mice was measured by q-PCR at 8 weeks postexposure; the numbers of spirochetes in these tissue

226 in, blocks viral fusion, and shows promising postexposure therapeutic activity.

227 In postexposure therapeutic trials in mice, a single dose o

228 potential to be developed as a life-saving, postexposure therapy against anthrax.

229 n mAbs, for achieving a safe and efficacious postexposure therapy for anthrax.

230 s have highlighted the need for an efficient postexposure therapy for Bacillus anthracis infection.

231 IFN-beta may have promise as an adjunctive postexposure therapy in filovirus infection.

232 Moreover, a 9-day postexposure therapy that was initiated 3 days after vir

233 Five MAbs functioned efficiently as postexposure therapy when administered as a single dose,

234 d 16NS1 also demonstrated marked efficacy as postexposure therapy, even when administered as a single

235 lonal antibodies (MAbs) that can function as postexposure therapy, we generated a panel of 82 new MAb

236 e goal of identifying MAbs that can serve as postexposure therapy, we investigated in detail the func

237 Three or six months postexposure, these animals and four naive controls were

238 yield after exposure varied as a function of postexposure time.

239 eks) showed essentially no shift at the same postexposure time.

240 rtality, particularly over a chronic (months postexposure) time scale, though not beyond naturally oc

241 nd held with unexposed cohorts for different postexposure times (2-96 weeks).

242 However, when held for long postexposure times, animals with previous exposure demon

243 idual MAbs protected mice well both pre- and postexposure to BoNT/A holotoxin.

244 ABA test showed that all the seeded cells postexposure to flow were viable, and significantly high

245 e group of mice was dosed and sacrificed 3 h postexposure to investigate tissue metabolite levels.

246 ion of this receptor that is seen in T cells postexposure to TGF-beta.

247 ercent recovery of activity at 7 min and 4 h postexposure to the inhibitor, were also determined.

248 Postexposure treatment (PET) of wild-type rabies virus (

249 ve also shown utility when administered as a postexposure treatment against filovirus infections, and

250 are includes assessment of side effects from postexposure treatment and surveillance for development

251 Successful postexposure treatment for inhalation anthrax is thought

252 nant vesicular stomatitis virus (rVSV), as a postexposure treatment for MARV haemorrhagic fever.

253 ility of inhaled antibodies as a fast-acting postexposure treatment for plague.

254 Vaccine and postexposure treatment have been effective in preventing

255 nical symptoms of rabies appear conventional postexposure treatment is unsuccessful.

256 ocess, but will also help to establish novel postexposure treatment modalities.

257 s become an important therapeutic target for postexposure treatment of botulism.

258 ccines, but also could be equally useful for postexposure treatment of filoviral infections.

259 y, we analyzed the potential of VSV-EBOV for postexposure treatment of rhesus macaques infected with

260 Public health messages must emphasize that postexposure treatment should be used only as a backup f

261 otential of RNA interference as an effective postexposure treatment strategy for people infected with

262 were treated with the rVSV MARV vectors as a postexposure treatment survived a high-dose lethal chall

263 Time to immunity and postexposure treatment were evaluated by immunizing hams

264 Here we show that early postexposure treatment with IFN-beta significantly incre

265 Postexposure treatment with MAb 201 can alleviate the vi

266 ne but demonstrates only limited efficacy in postexposure treatment.

267 Current postexposure treatments are inadequate at later stages o

268 al experimental conditions and suggests that postexposure treatments may need to be NiV strain specif

269 Two (66%) of three rhesus monkeys given four postexposure treatments of the pooled anti-ZEBOV siRNAs

270 infection, whereas all macaques given seven postexposure treatments were protected.

271 man exposure highlight the need for pre- and postexposure treatments.

272 mpleted screening, 27% had an initial but no postexposure tuberculin skin test, 12% were not screened

273 A new postexposure tuberculosis vaccine offers greatest potent

274 re significantly elevated (p < 0.05) in 24 h postexposure urine despite large between-subject variati

275 been demonstrated to inhibit anthrax toxin, postexposure use of DNI-based vaccines, including conjug

276 lyzed genome-wide transcriptional activities postexposure using an Affymetrix GeneChip microarray.

277 sera of individual PND 3 pups collected 1 hr postexposure utilizing ultra-high-pressure tandem mass s

278 These data provide evidence that postexposure vaccination can shorten the duration of ant

279 High postexposure vaccination effectiveness for preventing or

280 Thus postexposure vaccination enhanced the protection afforde

281 if VSVDeltaG-ZEBOV is safe or effective for postexposure vaccination in humans who have experienced

282 This result suggests that protection from postexposure vaccination may be antigen unspecific and d

283 primates and provides further evidence that postexposure vaccination may have utility in treating ex

284 Therefore, postexposure vaccination of adults with mycobacterial an

285 ently, rabies control in Tamil Nadu involves postexposure vaccination of humans after dog bites, wher

286 provides an accessible model for evaluating postexposure vaccination protocols that might be used in

287 Postexposure vaccination strategies rely on a rapid indu

288 t was offered, and provided his consent for, postexposure vaccination with an experimental vaccine av

289 ve immunotherapy with monoclonal antibodies, postexposure vaccination with constructs involving viral

290 In this patient, postexposure vaccination with VSVDeltaG-ZEBOV induced a

291 acy testing of smallpox vaccines in pre- and postexposure vaccine testing, which is important for pub

292 t rabies viruses (RABV) are promising rabies postexposure vaccines due to their prompt and potent sti

293 either method in the initial days (1 and 3) postexposure, we observed PrP(CWD) seeding activity and

294 nd RST3 isolates, except during the 2nd week postexposure, when the RST1 isolates displayed a markedl

295 loped significant airflow obstruction 10 min postexposure which persisted for 48 h.

296 olymorphonuclear leukocytes as early as 1 hr postexposure, which is indicative of mobilization of the

297 of gamma-H2AX foci was observed at 6 to 12 h postexposure, which was followed by activation of apopto

298 NAs were detected for up to 21, 21, and 24 h postexposure with E. chaffeensis, respectively, which we

299 ARV)-infected NHPs were treated 15 to 30 min postexposure with virus-specific IgG, with additional tr

300 ed hyaluronan synthase Has1 mRNA already 4 h postexposure, with a return to control level by 24 h.